These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 25771363)

  • 1. Theranostic Radiopharmaceuticals Based on Gold Nanoparticles Labeled with (177)Lu and Conjugated to Peptides.
    Ferro-Flores G; Ocampo-García BE; Santos-Cuevas CL; de María Ramírez F; Azorín-Vega EP; Meléndez-Alafort L
    Curr Radiopharm; 2015; 8(2):150-9. PubMed ID: 25771363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumoral fibrosis effect on the radiation absorbed dose of (177)Lu-Tyr(3)-octreotate and (177)Lu-Tyr(3)-octreotate conjugated to gold nanoparticles.
    Azorín-Vega EP; Zambrano-Ramírez OD; Rojas-Calderón EL; Ocampo-García BE; Ferro-Flores G
    Appl Radiat Isot; 2015 Jun; 100():96-100. PubMed ID: 25305748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multifunctional targeted therapy system based on (99m) Tc/(177) Lu-labeled gold nanoparticles-Tat(49-57)-Lys(3) -bombesin internalized in nuclei of prostate cancer cells.
    Jiménez-Mancilla N; Ferro-Flores G; Santos-Cuevas C; Ocampo-García B; Luna-Gutiérrez M; Azorín-Vega E; Isaac-Olivé K; Camacho-López M; Torres-García E
    J Labelled Comp Radiopharm; 2013 Nov; 56(13):663-71. PubMed ID: 25196028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular targeting radiotherapy with cyclo-RGDFK(C) peptides conjugated to 177Lu-labeled gold nanoparticles in tumor-bearing mice.
    Vilchis-Juárez A; Ferro-Flores G; Santos-Cuevas C; Morales-Avila E; Ocampo-García B; Díaz-Nieto L; Luna-Gutiérrez M; Jiménez-Mancilla N; Pedraza-López M; Gómez-Oliván L
    J Biomed Nanotechnol; 2014 Mar; 10(3):393-404. PubMed ID: 24730235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluorescent, Plasmonic, and Radiotherapeutic Properties of the
    Mendoza-Nava H; Ferro-Flores G; Ramírez FM; Ocampo-García B; Santos-Cuevas C; Azorín-Vega E; Jiménez-Mancilla N; Luna-Gutiérrez M; Isaac-Olivé K
    Mol Imaging; 2017 Jan; 16():1536012117704768. PubMed ID: 28654384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Panitumumab Modified with Metal-Chelating Polymers (MCP) Complexed to
    Aghevlian S; Lu Y; Winnik MA; Hedley DW; Reilly RM
    Mol Pharm; 2018 Mar; 15(3):1150-1159. PubMed ID: 29314858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kit for preparation of multimeric receptor-specific ⁹⁹mTc-radiopharmaceuticals based on gold nanoparticles.
    Ocampo-García B; Ferro-Flores G; Morales-Avila E; Ramírez Fde M
    Nucl Med Commun; 2011 Nov; 32(11):1095-104. PubMed ID: 21860334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiometallic Complexes of DO3A-Benzothiazole Aniline for Nuclear Medicine Theranostics.
    Park JA; Lee JW; Kim HK; Shin UC; Lee KC; Kim TJ; Chang Y; Kim KM; Kim JY; Lee YJ
    Mol Pharm; 2018 Mar; 15(3):1133-1141. PubMed ID: 29381860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual-Receptor-Targeted (DRT) Radiation Nanomedicine Labeled with
    Yook S; Cai Z; Jeong JJ; Lu Y; Winnik MA; Pignol JP; Reilly RM
    Mol Pharm; 2020 Apr; 17(4):1226-1236. PubMed ID: 32022567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Voxel-Based Dosimetry of Iron Oxide Nanoparticle-Conjugated
    Gupta A; Shin JH; Lee MS; Park JY; Kim K; Kim JH; Suh M; Park CR; Kim YJ; Song MG; Jeong JM; Lee DS; Lee YS; Lee JS
    Mol Pharm; 2019 Apr; 16(4):1498-1506. PubMed ID: 30821463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Local Radiation Treatment of HER2-Positive Breast Cancer Using Trastuzumab-Modified Gold Nanoparticles Labeled with
    Cai Z; Yook S; Lu Y; Bergstrom D; Winnik MA; Pignol JP; Reilly RM
    Pharm Res; 2017 Mar; 34(3):579-590. PubMed ID: 27987070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stability and Biodistribution of Thiol-Functionalized and (177)Lu-Labeled Metal Chelating Polymers Bound to Gold Nanoparticles.
    Yook S; Lu Y; Jeong JJ; Cai Z; Tong L; Alwarda R; Pignol JP; Winnik MA; Reilly RM
    Biomacromolecules; 2016 Apr; 17(4):1292-302. PubMed ID: 26974228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiation Nanomedicine for EGFR-Positive Breast Cancer: Panitumumab-Modified Gold Nanoparticles Complexed to the β-Particle-Emitter, (177)Lu.
    Yook S; Cai Z; Lu Y; Winnik MA; Pignol JP; Reilly RM
    Mol Pharm; 2015 Nov; 12(11):3963-72. PubMed ID: 26402157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancing Treatment Efficacy of
    Kuo HT; Merkens H; Zhang Z; Uribe CF; Lau J; Zhang C; Colpo N; Lin KS; Bénard F
    Mol Pharm; 2018 Nov; 15(11):5183-5191. PubMed ID: 30251544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and evaluation of Lys¹(α,γ-Folate)Lys³(¹⁷⁷Lu-DOTA)-Bombesin(1-14) as a potential theranostic radiopharmaceutical for breast cancer.
    Aranda-Lara L; Ferro-Flores G; Azorín-Vega E; Ramírez FM; Jiménez-Mancilla N; Ocampo-García B; Santos-Cuevas C; Isaac-Olivé K
    Appl Radiat Isot; 2016 Jan; 107():214-219. PubMed ID: 26545016
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Rizvi SFA; Naqvi SAR; Roohi S; Sherazi TA; Rasheed R
    Mol Biol Rep; 2018 Dec; 45(6):1759-1767. PubMed ID: 30143975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a ¹⁷⁷Lu-labeled RGD derivative for targeting angiogenesis.
    Ju CH; Jeong JM; Lee YS; Kim YJ; Lee BC; Lee DS; Chung JK; Lee MC; Jeong SY
    Cancer Biother Radiopharm; 2010 Dec; 25(6):687-91. PubMed ID: 21204763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of theranostic active-targeting boron-containing gold nanoparticles for boron neutron capture therapy (BNCT).
    Wu CY; Lin JJ; Chang WY; Hsieh CY; Wu CC; Chen HS; Hsu HJ; Yang AS; Hsu MH; Kuo WY
    Colloids Surf B Biointerfaces; 2019 Nov; 183():110387. PubMed ID: 31394419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiometal-Dependent Biological Profile of the Radiolabeled Gastrin-Releasing Peptide Receptor Antagonist SB3 in Cancer Theranostics: Metabolic and Biodistribution Patterns Defined by Neprilysin.
    Lymperis E; Kaloudi A; Sallegger W; Bakker IL; Krenning EP; de Jong M; Maina T; Nock BA
    Bioconjug Chem; 2018 May; 29(5):1774-1784. PubMed ID: 29664606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results.
    Nock BA; Kaloudi A; Lymperis E; Giarika A; Kulkarni HR; Klette I; Singh A; Krenning EP; de Jong M; Maina T; Baum RP
    J Nucl Med; 2017 Jan; 58(1):75-80. PubMed ID: 27493272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.